Mycoskin (Ciclopirox Olamine)

Ciclopirox olamine works by chelating polyvalent metal ions like iron and aluminum that are essential cofactors for fungal enzymes. This chelation disrupts metal‑dependent enzymatic processes required for cellular respiration and membrane transport, inhibiting fungal growth and leading to cell death across dermatophytes, yeasts and some molds.

The specific dosing regimen for Mycoskin is set by the prescribing clinician based on infection type, severity, patient age and treatment area. Typically, a thin layer is applied to the affected skin once or twice daily for the duration recommended by the healthcare provider.

Safety data for ciclopirox olamine during pregnancy and lactation are limited. Use is permitted only if the potential benefit justifies any potential risk, and this decision must be made by a qualified healthcare professional.

To order Mycoskin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike azole or allylamine topicals, ciclopirox olamine does not target ergosterol synthesis, reducing the risk of cross‑resistance. It offers broad‑spectrum activity against dermatophytes, Candida species and some molds, though potency may vary against certain resistant strains. Choice of therapy depends on the clinical scenario and susceptibility patterns.

Mycoskin should be stored at ambient temperature, preferably below 25 °C, in its original container to protect it from moisture and direct sunlight. Keep the product tightly closed when not in use and out of reach of children.

Mycoskin is applied topically to clean, dry skin. A thin film is spread over the affected area, usually once or twice daily, and gently rubbed in until it disappears. Hands should be washed after application, and the treated area should be allowed to dry before covering with clothing.

Rare but serious risks include severe contact dermatitis, skin ulceration, and systemic hypersensitivity reactions such as urticaria or anaphylaxis. If signs of severe irritation, swelling, or systemic allergic response appear, discontinue use immediately and seek medical attention.

Mycoskin should not be used by individuals with known hypersensitivity to ciclopirox olamine or any excipients in the formulation. It is also contraindicated on extensive open wounds, severe burns, or mucous membranes, and should be avoided when a healthcare professional determines that risks outweigh benefits.